[A22-135] Pembrolizumab (cervical cancer) – Addendum to Commission A22-70

Last updated 02.02.2023

Project no.:
A22-135

Commission:
Commission awarded on 21.12.2022 by the Federal Joint Committee (G-BA).

Report type:
Addendum

Status:
Commission completed

Department/Division:
Drug Assessment

Topic:
Cancer

Indication:

Adult patients with persistent, recurrent, or metastatic cervical cancer whose tumours express PD-L1 with a CPS ≥ 1

Result of dossier assessment:
  • First-line patients for whom cisplatin or carboplatin + paclitaxel ± bevacizumab is a suitable therapy of physician’s choice: After addendum now: indication of major added benefit
  • First-line patients for whom cisplatin or carboplatin + paclitaxel ± bevacizumab is no suitable therapy of physician’s choice: Unchanged after addendum: added benefit not proven
  • Patients after first-line chemotherapy and for whom further antineoplastic therapy is an option: Unchanged after addendum: added benefit not proven
Note:

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Federal Joint Committee (G-BA)

2023-02-02 A G-BA decision was published.

G-BA documents on this decision

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form